News

Generative AI tools are rapidly embedding themselves into R&D workflows, offering clear efficiency gains during early research and drafting. However, when dealing with confidential technical developments, unpublished brand concepts, or proprietary software, unmonitored AI use introduces significant legal and commercial risks. In our latest briefing, we highlight key considerations for businesses integrating generative AI into their innovation pipelines.

As pharmaceutical manufacturers face increasing pressure to maintain production continuity, ensure regulatory compliance, and manage ageing equipment, the traditional approach to spare parts management is being challenged. Long OEM lead times, component obsolescence, and supply chain disruptions are exposing critical vulnerabilities across regulated manufacturing facilities.

The endorsed funder pathway of the Global Talent Visa (GTV), managed by UKRI, has been expanded to include over 100 UK research-intensive businesses.

Whether you're developing a new life science facility, upgrading an existing laboratory, or creating a mixed-use environment that combines research, office and collaboration spaces, getting the fundamentals right from the outset is critical.

The growing complexity of antibody therapeutics and complement-targeted medicines is increasing demand for reliable immune analysis tools. Creative Biolabs expands complement C1q research capabilities with specialized proteins, binding assays, and functional analysis services to support biologics development.

Artificial intelligence is changing how organisations think about business development and how to grow their business. It can process vast quantities of information, identify patterns and generate material at remarkable speed. Using pattern recognition and stolen data, do you really want to rely on this for your business reputation?

Bruntwood SciTech, the UK’s largest property platform dedicated to the growth of tech, innovation and science sectors, has surpassed a landmark moment at Manchester Science Park with the practical completion of Greenheys, the £60 million laboratory and workspace development designed to support the needs and ambitions of cutting-edge science, technology and innovation businesses.

HGF has strengthened its European Life Sciences practice with the appointment of Dr Russell Thom, who joins the firm as a Partner 1st August 2026.

Four systems. One spreadsheet holding it together. Spinout or growth-stage, that's the real reason trial timelines slip, not the studies themselves. Here's what's actually going on.

Across the world, climate zones represent diverse environmental conditions, each with unique temperature and humidity profiles. This variety in climates plays a significant role in the stability and efficacy of pharmaceutical products. Understanding how these varying climatic conditions can affect drug characteristics is crucial in the pharmaceutical industry to ensure that medications remain safe and effective regardless of where they are stored or used.
This blog offers an overview of the ICH climate zones and the role they play in stability testing.

Newcastle, UK, 30 July 2026: Iksuda Therapeutics (Iksuda), the developer of class leading, antibody drug conjugates (ADCs), today announces that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for IKS04, a CA242-directed ADC, enabling assessment in a Phase 1 trial in patients with gastrointestinal (GI) cancers.

Your first conversation with an investor may happen before you’ve met them. Before an angel investor hears your pitch, a venture capital firm joins a meeting, or a funding panel reviews your application, we know they will look up your company online. That research will include your website.

HGF has been listed in the UK's Best Workplaces for Women™ 2026 rankings by Great Place to Work®, recognising organisations that are creating workplaces where women can thrive and progress in their careers.

Pioneer Group has announced the launch of new regional accelerator programmes designed to support early-stage life science and tech companies accelerate their journey to market.

The UK's pharmaceutical manufacturing landscape has undergone a radical transformation over the past fifteen years, moving from an era dominated by large-scale "blockbuster" drugs to a sophisticated ecosystem of personalised medicine and advanced therapies. Navigating this complexity requires a fundamental rethink of how we design, build, and operate facilities.

At Arttia Creative, we help innovative healthcare, biotech and life science organisations communicate with clarity and confidence, combining scientific understanding with creative communications and meticulous project processes. Our monthly digital marketing support is designed for companies like yours that need consistent, strategic marketing activity without the pressure of building an in-house marketing team.

Scientists led by Dr Talat Nasim at the University of Bradford uncover a novel dual-action approach that restores critical cellular signalling pathways implicated in pulmonary arterial hypertension (PAH), a life-threatening lung disease. These findings have been published in Research Connections, a peer-reviewed scientific journal published by Oxford University Press.

Patient recruitment causes most clinical trial delays. UK data shows why speed to the first patient matters, and how digital recruitment and consent tools can help close that gap.

Creative Biolabs is highlighting an integrated antibody CDMO service framework designed to connect high-throughput recombinant antibody production with process development, manufacturing, quality control, and regulatory support.

From small segregation pods to large-scale off-site constructed container facilities, East Anglian contamination control specialists Guardtech have all your Aerospace cleanroom bases covered

The Biotech Bikers Golden Triangle Ride takes place on Saturday 12 September 2026, bringing together cyclists from across the biotech, life sciences and biomedical innovation community.

Pioneer Group, a specialist life science infrastructure and venture building business, and Firoka, a hospitality and real estate group, have secured unanimous resolution to grant planning permission for the transformation of Ozone Leisure Park in Oxford.

The decision marks a major milestone for Ozone Oxford, a new mixed-use campus that will bring together research, workspace, leisure and community facilities on the existing Ozone Leisure Park site.

Creative Biolabs, a leading biotechnology service provider specializing in AI-based antibody discovery and engineering, has announced its upcoming webinar titled "Upcoming Webinar: Novel Platforms for Preclinical Antibody Discovery."

As the UK’s life sciences sector continues to grow, businesses are increasingly looking for environments that offer more than just laboratory space. Access to talent, specialist infrastructure, research expertise and opportunities for collaboration are becoming critical factors in supporting innovation and commercial success.

The MHRA used to move in lockstep with the EMA. Now it doesn't. Here's what changed, what's coming, and what it means for your trials.

VectorBuilder, a global leader in gene delivery technologies, is launching a major update to VectorBee, its acclaimed 100% free DNA software created to help researchers view, edit, annotate, and analyze DNA and protein sequences with greater control and flexibility. Best of all, users transition seamlessly from design to order, avoiding the pain point of turning vector ideas into reality.

Ready to improve your healthcare search visibility? Discover in this article How to Work With Your Healthcare SEO Agency to Improve Search Visibility.

The University of Manchester spinout CareLoop Health is reporting strong early traction following a £1.8m funding round.

The backing came from NPIF II – PXN Equity Finance, the GMC Life Sciences Fund by PXN Ventures, Verge HealthTech Fund and SFC Capital, supporting the business to scale its technology and expand clinical adoption across the UK and internationally.

Manchester Metropolitan University is in the final stages of recruitment for its September 2026 Degree Apprenticeship cohorts. Employers looking to develop future talent or upskill existing employees are encouraged to secure their place now and build the skilled, future-ready workforce needed for tomorrow.

RoslinCT, a leading global cell therapy Contract Development and Manufacturing Organisation, has announced a strategic partnership with BlueRock Therapeutics, a leader in stem cell therapeutic development, to broaden access to clinical-grade pluripotent stem cell lines for cell therapy developers.